Finance entity
All 5 tracked stories fall under one category: markets. Sentiment skews less negative than the wider beat, at 0% negative against 28% across all 3903 Finance stories in the same window. Of the tracked stories, 2 of 5 also mention AstraZeneca, the most common co-covered peer.
Last mentioned: Aug 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 5 tracked stories fall under one category: markets. Sentiment skews less negative than the wider beat, at 0% negative against 28% across all 3903 Finance stories in the same window. Of the tracked stories, 2 of 5 also mention AstraZeneca, the most common co-covered peer. That works out to roughly 0.2 stories per week across a 166-day span. Each story carries 2.8 original sources on average, compared with 2.8 for the broader beat in this window. The 6.8 average consequence score is above the beat benchmark of 6.3 in the same window. This profile follows 5 Finance stories mentioning Bristol Myers Squibb across the period from February 19, 2026 to August 3, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 3903 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bristol Myers Squibb. Shared-story counts are live from our verified record — not editorial picks.
AstraZeneca shares plummeted in London trading after reports of merger talks with Bristol Myers Squibb, as the market priced in execution risk, regulatory peril, and potential overpayment for a deal that would create a £300bn giant.
The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Source: Cory Renauer (us) · fool.com
In a market where the S&P 500 yields a paltry 1.4%, Pfizer and Bristol Myers Squibb offer income investors a rare combination of outsized yields and deep value. With forward P/E ratios below 11, these beaten-down pharma giants could re-rate as pipeline successes materialize.
The Juvenile Idiopathic Arthritis (JIA) market is projected to expand at a 5.6% CAGR through 2036, reaching multi-billion dollar valuations driven by advanced biologic therapies. Major pharmaceutical players including Bristol-Myers Squibb and Novartis are positioned to capture significant share with next-generation treatments.
Bristol Myers Squibb is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
